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CASE REPORT
ANAL SQUAMOUS CARCINOMA: A NEW AIDS-DEFINING CANCER?  
CASE REPORT AND LITERATURE REVIEW
Marcelo CORTI(1), María F. VILLAFAÑE(1), Esteban MARONA(2) & Daniel LEWI(3)
SUMMARY
Squamous anal cell carcinoma is a rare malignancy that represents the 1.5% to 2% of all the lower digestive tract cancers. However, 
an increased incidence of invasive anal carcinoma is observed in HIV-seropositive population since the widespread of highly active 
antiretroviral therapy. Human papillomavirus is strongly associated with the pathogenesis of anal cancer. Anal intercourse and a high 
number of sexual partners appear to be risk factors to develop anal cancer in both sexes. Anal pain, bleeding and a palpable lesion 
in the anal canal are the most common clinical features. Endo-anal ultrasound is the best diagnosis method to evaluate the tumor 
size, the tumor extension and the infiltration of the sphincter muscle complex. Chemoradiotherapy plus antiretroviral therapy are the 
recommended treatments for all stages of localized squamous cell carcinoma of the anal canal in HIV-seropositive patients because of 
its high rate of cure. Here we present an HIV patient who developed a carcinoma of the anal canal after a long time of HIV infection 
under highly active antiretroviral therapy with a good virological and immunological response.
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INTRODUCTION
Anal intraepithelial neoplasm (AIN) and squamous anal cell 
carcinoma (SACC) are uncommon malignancies that represent the 
1.5% to 2% of all digestive tract cancers9. However, in the last two 
decades, the incidence of SACC has increased in relation with the human 
immunodeficiency virus (HIV) infection, especially in men who have 
sex with men (MSM). In addition, patients with a longer history of HIV 
infection (> 15 years) have a 12-fold higher rate of SACC in comparison 
with those who have < 5 years5. Although the screening for AIN and the 
vaccination against human papillomavirus (HPV) oncogenic subtypes 
may reduce the risk for development of anal cancer, at present, these 
neoplasms remain as a significant comorbidity in HIV/AIDS patients.
Here, we present a patient with AIDS who develop an SACC after a 
long time history of HIV infection and under highly active antiretroviral 
therapy (HAART).
CASE REPORT
A 58-year-old homosexual male with diagnosis of HIV infection since 
1986 was referred to our HIV-AIDS Division because he presented anal 
pain and several episodes of proctorrhagia. Anal examination showed 
multiple lesions compatible with condyloma acuminatum (anogenital 
warts). A digital examination was performed and detected an intra-anal 
indurated lesion. The 3D endo-rectal ultrasonography demonstrated 
the presence of an intra-anal lesion of 3 cm x 1 cm of diameters that 
involve the anal sphincter muscle. Abdominal computed tomography 
was negative to detect prerirectal, internal iliac or inguinal adenopathies 
(T3N0) (Fig. 1). A videocolonoscopy was made and multiple biopsy 
smears of the lesion were performed. Histopathological examination 
revealed anal mucosae with preservation of squamous epithelium and 
regular number of koilocytes (Fig. 2). In other area, a proliferation of 
atypical cells that infiltrate the stromal was observed (Fig 3). Final 
histopathological diagnosis was squamous cell carcinoma in the anal 
canal. At the time of neoplasm diagnosis, the plasma viral load was 
undetectable (< 20 copies/mL) and the CD4 T-cell count was 373 cell/µL.
He was treated with the combination of HAART based on 
tenofovir plus darunovir boosted with ritonavir and raltegravir, three 
dimensional radiotherapy and chemotherapy according with Nigro 
scheme (5-Fluoruracil + Mitomycin C). During the first three months 
of chemotherapy, the patient presented a reduction of CD4 T-cell count 
below 200 cell/µL but there were no changes in the HIV viral load that 
remained undetectable. A new 3D endo-rectal ultrasound was performed 
after treatment and showed the resolution of the tumoral mass with the 
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normal aspect of both sphincters (Fig. 4). After 18 months of follow-up 
the patient is still in a good clinical condition, with undetectable viral 
load (< 20 copies/mL) and CD4 T-cell count > 200 cell/µL.
DISCUSSION
Anal cancer may arise from the anal canal or from the anal margin; 
85% of the anal cancers involve the anal canal and the remaining 
15% occur on the anal margin. Anal carcinomas are characterized by 
aggressive local invasion including the infiltration of the sphincter 
muscle. In contrast, the tumors originated in the peri-anal skin have a 
better prognosis and their evolution is similar to other skin cancers3. Anal 
cancer is much more frequent in HIV-positive MSM in comparison with 
HIV-seronegative persons13. Some evidences suggest that male partners 
may be a reservoir for high-risk HPV subtypes, probably located in penile 
lesions. HPV infection is highly prevalent in sexually active men and 
HPV-16 seems to be the most common subtype detected in anal lesions. 
The prevalence of HPV-16 in this population range from 73% to 93%2. 
Additionally, multiple subtypes of infection are more frequent in men 
than in women7.
One of the most important risk factors for HPV infection in 
homosexual men is the HIV coinfection. The probability to develop anal 
cancer has been reported as two to 14 times higher in HIV-positive MSM 
in comparison with those who are HIV-negative20. Anal cancer presents 
a higher incidence than other HPV-related genital cancers as vulvar, 
vaginal or penile tumors20. Between 1973 and 2004, the rate of anal cancer 
increased in the United States from 0.5 to 1.3 per 100,00012. Finally, anal 
cancer is also frequent in women that practice receptive anal intercourse. 
Fig. 1 - 3D endo-rectal ultrasonography demonstrated the presence of an intra-anal lesion of 
3 cm x 1 cm of diameters that involve the anal sphincter muscle. (arrow)
Fig. 2 - Hematoxylin-eosin staining of tissue (40X): infiltrating sheets and islands of squamous 
epithelium surrounded by fibrous connective tissue with chronic inflammatory cell infiltrate.
Fig. 3 - Hematoxylin-eosin staining of biopsy smear (100X): islands of squamous tumor cells 
with nuclear pleomorphism and keratin formation.
Fig. 4 - Normal aspect of 3D endo-rectal ultrasonography after treatment. 
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The relation between anal cancer and receptive anal intercourse is similar 
in both sexes and is independent of immunosuppression11.
As other non-AIDS defining malignancies, as lung cancer, Hodgkin’s 
disease and liver carcinoma, the incidence of AIN and SACC does not 
seem to correlate with the CD4 T-cell counts8. Additionally, the risk of 
anal cancer not decline with the widespread of HAART15. High-grade of 
AIN is the precursor lesion to anal cancer similar to cervical intraepithelial 
neoplasia (CIN) and cervical cancer3.
Clinical presentation of anal cancer in HIV-seropositive patients 
does not differ substantially with the general population10. Anal pain, 
anal fissure or fistulae, diarrhea, bleeding and exophytic verrucous 
anal and intra-anal infiltrative lesions are the most common clinical 
manifestations. The presence of these clinical manifestations should 
be carefully evaluated, especially in those patients that refer anal pain, 
including the examination under anesthesia and multiple biopsy smears 
should be obtained.
When the patients refer rectal tenesmus or painful defecation, the 
clinician should suspect the probable infiltration of the sphincter muscle4.
A careful histopathological examination of the biopsy smears is very 
important in these kind of patients; in this aspect, it is important to arise 
the regional extension of the tumor and the histopathological grade that 
is based on the same criteria used for CIN from normal, AIN-1, AIN-2, 
AIN-3 or carcinoma in situ10,18. Tumors longer than 5 cm in diameter (T3) 
and with metastases in regional lymph nodes (N1-3) have an increased 
risk for recurrence after chemoradiation3. Endo-anal ultrasound represents 
the better diagnosis method to determine the grade of tumor infiltration 
and to evaluate the involvement of the sphincter muscle complex, as we 
can see in our patient.
HPV play an important role in the pathogenesis of both CIN and 
AIN, and HPV DNA was found in many anal cancers biopsy smears14,15.
Predictive factors to develop AIN-2, AIN-3 or anal carcinoma in 
HIV positive patients include the infection by HPV oncogenic subtypes, 
especially HPV 16 and the infection due to multiple subtypes of HPV6,8,13.
Although HAART reduce the incidence of opportunistic infections 
and AIDS-defining cancers, the incidence of SACC is increasing since 
the widespread use of antiretroviral therapy8. The cumulative incidence 
of AIN-2, 3 in a two large cohort studies was 37% and 34%, respectively, 
over a three and four-year period of follow up1,13. PALEFSKY et al.14 
demonstrate that the use of HAART does not provide a greater protection 
against AIN and for other malignancies related with HPV as CIN. In the 
majority of the cases, the standard treatment for AIDS-associated anal 
cancer is based on chemoradiotherapy regimen with 5-fluoruracil (5FU) 
and mitomycin (MMC) named as Nigro scheme and three dimensional 
radiotherapy, as we use in our patient1,19. SEO et al.17 reported that the 
combination of HAART and chemoradiotherapy is as safe and effective 
for immunodeficient and immunocompetent patients. Anal cancer is 
usually curable. The three major prognostic factors are the site (anal 
canal vs. perianal skin), the size (primary tumors < 2 cm in size have 
better prognosis), and the nodal status.
VATRA et al.19 compared 20 HIV-positive patients with diagnosis 
of SACC with 24 HIV-negative subjects. Survival rates at one year after 
chemoradiotherapy with preserved anal sphincter was significantly 
higher in the HIV-negative group (88%) in comparison with the HIV-
positive patients (45%) (p < 0.05). At three years, the median survival 
in the HIV-seropositive group was 18 months, significantly shorter 
than the 28 months observed in the HIV-negative (p < 0.001). Also, in 
this study, the CD4 T cell count for less than 250 cell/µL at the time 
of neoplasm diagnosis was a predictive factor of poor prognosis and 
a shorter survival.
In conclusion, we consider that SACC should be included as an 
AIDS-defining illness based on the high rate incidence in this population. 
A better prognosis is related with the early diagnosis and the treatment 
based on the combination of HAART plus chemoradiotherapy.
RESUMO
Carcinoma de células escamosas do canal anal: a nova neoplasia 
associada com AIDS?
O carcinoma de células escamosas do canal anal é uma malignidade 
rara que representa 1,5% a 2% de todos os cânceres do trato 
gastrointestinal inferior. Entretanto, é observada uma incidência 
aumentada do carcinoma anal invasivo, na população soropositiva para 
o HIV desde a difusão da terapia antirretroviral altamente ativa. O vírus 
do papiloma está fortemente associado com a patogênese do câncer anal. 
Sexo anal e um alto número de parceiros sexuais parecem ser os fatores 
de risco para desenvolver câncer anal em ambos os sexos. Dor anal, 
sangramento e lesão palpável no canal anal são as manifestações clínicas 
mais comuns. O ultrassom endoanal é o melhor método diagnóstico 
para avaliar o tamanho do tumor, sua extensão e a infiltração para o 
complexo do músculo esfincteriano. A quimioradioterapia mais terapia 
antirretroviral é o tratamento recomendado para todos os estádios do 
carcinoma localizado de células escamosas do canal anal nos pacientes 
HIV soropositivos, devido a sua alta taxa de cura. Apresentamos um 
paciente que desenvolveu carcinoma do canal anal depois de um longo 
tempo de infecção por HIV sob tratamento com a terapia antirretroviral 
altamente ativa, com boa resposta virológica e imunológica.
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